WELCOME TO Million Health Pharmaceuticals

Tolvamac is indicated in patients for the treatment of patients with hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). Tolvamac is also indicated for hypervolemic and euvolemic hyponatremia (sodium concentration <125 mmol l–1) in patients with heart failure and cirrhosis. In this US country use this medicine frequently.

Tolvaptan is a kind of selective and competitive arginine vasopressin receptor 2 antagonist. Vasopressin performs action on the V2 receptors found in the walls of the vasculature and luminal membranes of renal collecting ducts. By blocking V2 receptors in the renal collecting ducts, aquaporins do not go inside themselves into the walls hence prohibiting water absorption.

This action basically results in a rise in urine volume, lesser the urine osmolality, and increase electrolyte-free water clearance to decrease intravascular volume and a higher serum sodium levels. Tolvaptan is essentially required for heart failure patients as they have higher serum levels of vasopressin.

ADME properties


Time to peak plasma concentration of Tolvamac is 2-4 hours The absolute bioavailability is unknown. Food will not affect the bioavailability of Tolvamac.


Volume of distribution in healthy subjects is 3L/kg. The plasma protein bounding of Tolvamac is 99%


Tolvamac is metabolism occurs by CYP3A4 enzyme in the liver.


Less than 1% is eliminated in the urine (unchanged form) and via faecal is very little amount of renal elimination. In oral dose, half-life of Tolvamac is 12 hours.


Ingredients : Tolvaptan
Strength : 15mg
Package : 10 tablets in 1 strips

Dosage and administration of Tolvamac 15mg

Tolvamac tablet is Indicated for adults with clinically significant euvolemic or hypervolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia which is symptomatic and has opposed correction with fluid restriction), contains patients with heart failure, cirrhosis, and SIADH Initial: 15 mg PO qDay Maintenance: May increase to 30 mg qDay after at least 24 hr to achieve the optimal serum sodium level; not to exceed 60 mg/day Not to exceed 30 days of treatment

Polycystic Kidney Disease

In this case Tolvamac tablet Indicated to slow kidney function reduce in adults at harm of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) Initial: 45 mg PO taken on waking and 15 mg taken 8 hr later (ie, 60 mg/day) Advice the patients to drink enough water to avoid thirst or dehydration Administration of Tolvamac should be without food Grape juice should be avoided during therapy with Tolvamac


Administrating monotherapy oral doses up to 480 mg and multiple doses up to 300 mg once in a day for 5 days have been well accepted in studies in healthy subjects. There is no essential antitoxin for Tolvamac intoxication. The signs and symptoms of an acute overdose can be expected to be those of extra pharmacologic effect: an increase in serum sodium concentration, polyuria, thirst, and dehydration / hypovolemia.


The conditions like Hypernatremia, hypovolemia, and/or dehydration; provoke patient to drink whenever thirsty Risk of potassium level increased Tolvamac 15mg produce Osmotic demyelination syndrome is a harm along with too-fast correction of hyponatremia

Tolvamac 15mg can develops serious and likely fatal liver injury; acute liver failure needed liver transplantation reported; discontinue if laboratory abnormalities or signs or symptoms of liver injury are apparent.


Drug-drug interaction of Tolvamac 15mg

Tolvamac combination with moderate CYP3A4 inhibitors will increase in exposure of Tolvamac 15mg . Combination of lovastatin, digoxin, furosemide, and hydrochlorothiazide has no clinically relevant impact on the exposure to Tolvamac 15mg When interaction with P-gp inhibitors will have reductions in the dose of Tolvamac 15mg

Concomitant use of rifampin and Tolvamac 15mg decrease exposure to tolvaptan by 85%. Tolvamac 15mg co administration with strong CYP3A4 inhibitors like ketoconazole will have highest labelled dose would be normal to cause an even heavy increase in exposure.


Tolvamac 15mg is contraindicated with following condition as Patients with autosomal dominant polycystic kidney disease because the drug causes severe and possible fatal liver injury. Required in acutely raised serum sodium Patients inability to sense Hypovolemic /hyponatremia

Quick Contact

Prescription upload


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.